Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, September 2011, Pages: 79

Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global SCLC therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SCLC therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis estimated the small cell lung cancer (SCLC) therapeutics market to be worth $277.8m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 3.4% over the next eight years to reach $362.3m in 2018. The growth during 2005-2010 was primarily attributed to the launch of an oral form of Hycamtin (topotecan). The steady growth rate during the forecast period is attributed to the expected launch of Amrubicin (SM-5887) in the US and Europe for the treatment of relapse/refractory SCLC patients, as well as a weak late stage pipeline with no molecules to treat newly diagnosed patients.

Scope

The report provides information on the key drivers and challenges of the SCLC therapeutics market. Its scope includes -
- Annual data on the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for SCLC therapeutics, with historic data from 2005 to 2010 and forecasts to 2018.
- Pipeline analysis data providing information on the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for SCLC fall under major therapeutic classes such as topoisomerase II inhibitors, Pan Bcl-2 inhibitors, topoisomerase I inhibitors, IGF-R1 inhibitors/hedgehog pathway inhibitors, and tyrosine kinase inhibitors.
- Analysis of the current and future competition in the global SCLC market is provided. The key market players covered are Celgene Corporation and Cephalon Inc.
- An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics coverage, including strategic a competitor assessment, market characterization and unmet needs analysis, as well as their implications for the SCLC therapeutics market.
- Analysis of key recent licensing and partnership agreements in the SCLC therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global SCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global SCLC therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global SCLC therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Small Cell Lung Cancer (SCLC) Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Risk Factors
2.5 Pathophysiology
2.6 Signs and Symptoms
2.7 Staging
2.7.1 Stages of SCLC
2.7.2 Anatomic Stage Classification
2.7.3 Tests and Procedures Used in the Staging Process
2.8 Survival Rates for SCLC
2.8.1 Limited-Stage SCLC
2.8.2 Extensive-Stage SCLC
2.9 Recurrent SCLC
2.10 Diagnosis
2.10.1 Chest X-ray
2.10.2 Physical Exam and History
2.10.3 CT Scan (CAT Scan) of the Brain, Chest, and Abdomen
2.10.4 PET Scan (Positron Emission Tomography Scan)
2.10.5 Sputum Cytology
2.10.6 Bronchoscopy
2.10.7 Fine-Needle Aspiration (FNA) Biopsy of the Lung
2.10.8 Thoracoscopy
2.10.9 Thoracentesis
2.11 Treatment and Management Pattern of SCLC
2.11.1 Surgery
2.11.2 Chemotherapy
2.11.3 Radiation Therapy
2.11.4 Laser Therapy
2.11.5 Endoscopic Stent Placement
2.12 Chemotherapy Regimens
2.12.1 Subsequent Chemotherapy
2.13 Treatment Options by Stage
2.14 Pipeline Report Guidance
3 Small Cell Lung Cancer Therapeutics - Market Characterization
3.1 SCLC Therapeutics Market Size (2005-2010) – Global
3.2 SCLC Therapeutics Market Forecast (2010-2018) – Global
3.3 SCLC Therapeutics Market Size (2005-2010) – The US
3.4 SCLC Therapeutics Market Forecast (2010-2018) – The US
3.5 SCLC Therapeutics Market Size (2005-2010) – The UK
3.6 SCLC Therapeutics Market Forecast (2010-2018) – The UK
3.7 SCLC Therapeutics Market Size (2005-2010) – France
3.8 SCLC Therapeutics Market Forecast (2010-2018) – France
3.9 SCLC Therapeutics Market Size (2005-2010) – Germany
3.10 SCLC Therapeutics Market Forecast (2010-2018) – Germany
3.11 SCLC Therapeutics Market Size (2005-2010) – Italy
3.12 SCLC Therapeutics Market Forecast (2010-2018) – Italy
3.13 SCLC Therapeutics Market Size (2005-2010) – Spain
3.14 SCLC Therapeutics Market Forecast (2010-2018) – Spain
3.15 SCLC Therapeutics Market Size (2005-2010) – Japan
3.16 SCLC Therapeutics Market Forecast (2010-2018) – Japan
3.17 Drivers and Barriers for the SCLC Therapeutics Market
3.17.1 Drivers for the SCLC Therapeutics Market
3.17.2 Barriers for the SCLC Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 SCLC Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Profiles of the Commonly Used Products and Regimens in the SCLC Therapeutics Market
4.2.1 Calsed (amrubicin hydrochloride, SM-5887)
4.2.2 Cisplatin and Etoposide Regimen
4.2.3 Carboplatin and Etoposide Regimen
4.2.4 Cisplatin and Irinotecan Regimen
4.2.5 Hycamtin (topotecan)
4.3 Key Takeaway
5 SCLC Therapeutics Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Small Cell Lung Cancer Pipeline Analysis – Pipeline by Clinical Phases of Development
5.3.1 SCLC Therapeutics – Phase III Clinical Pipeline
5.3.2 SCLC Therapeutics – Phase II/III Clinical Pipeline
5.3.3 SCLC Therapeutics – Phase II Clinical Pipeline
5.3.4 SCLC Therapeutics – Phase I/II Clinical Pipeline
5.3.5 SCLC Therapeutics – Phase I Clinical Pipeline
5.3.6 SCLC Therapeutics – Preclinical Pipeline
5.4 SCLC Pipeline by Mechanism of Action
5.5 SCLC Technology Trends Analytical Framework
5.6 SCLC Therapeutics – Promising Drugs under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 Alimta (pemetrexed) in Combination with Carboplatin
5.7.2 Camtobell (belotecan, CKD-602) plus Cisplatin
6 Small Cell Lung Cancer Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in SCLC Therapeutics Clinical Trials
7 Small Cell Lung Cancer Therapeutics - Strategic Assessment
7.1 Future Market Competition Scenario
8 Small Cell Lung Cancer Therapeutics - Future Players in The Market
8.1 Introduction
8.2 Company Profiles
8.2.1 Celgene Corporation
8.2.2 Cephalon Inc.
9 Small Cell Lung Cancer Therapeutics - Licensing and Partnership Deals
10 Small Cell Lung Cancer Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Newly Diagnosed SCLC Cases in Major Markets, 2010
Table 2: SCLC First-line Chemotherapy Regimens
Table 3: SCLC Chemotherapy Regimens for Relapse/Refractory
Table 4: SCLC Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 5: SCLC Therapeutics Market, Global, Forecast ($m), 2010–2018
Table 6: SCLC Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 7: SCLC Therapeutics Market, The US, Revenue ($m), 2010–2018
Table 8: SCLC Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 9: SCLC Therapeutics Market, The UK, Forecast ($m), 2010–2018
Table 10: SCLC Therapeutics Market, France, Revenue ($m), 2005–2010
Table 11: SCLC Therapeutics Market, France, Forecast ($m), 2010–2018
Table 12: SCLC Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 13: SCLC Therapeutics Market, Germany, Forecast ($m), 2010–2018
Table 14: SCLC Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 15: SCLC Therapeutics Market, Italy, Forecast ($m), 2010–2018
Table 16: SCLC Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 17: SCLC Therapeutics Market, Spain, Forecast ($m), 2010–2018
Table 18: SCLC Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 19: SCLC Therapeutics Market, Japan, Forecast ($m), 2010–2018
Table 20: SCLC Therapeutics – Phase III Clinical Pipeline, 2011
Table 21: SCLC Therapeutics – Phase II/III Clinical Pipeline, 2011
Table 22: SCLC Therapeutics – Phase II Clinical Pipeline, 2011
Table 23: SCLC Therapeutics – Phase I/II Clinical Pipeline, 2011
Table 24: SCLC Therapeutics – Phase I Clinical Pipeline, 2011
Table 25: SCLC Therapeutics – Preclinical Pipeline, 2011
Table 26: Mechanisms of Action That Constitute the Others in the Above Pie Chart
Table 27: SCLC Therapeutics – Promising Drugs Under Clinical Development, 2011
Table 28: SCLC Therapeutics – Clinical Trials by Country, 2011
Table 29: SCLC Therapeutics – Clinical Trials by Phase, 2011
Table 30: SCLC Therapeutics – Clinical Trials by Status, 2011
Table 31: SCLC Therapeutics – Clinical Trials, by Overall Sponsors, 2011
Table 32: SCLC Therapeutics – Clinical Trials by Prominent Sponsors, 2011
Table 33: SCLC Therapeutics – Top Companies Participating in Clinical Trials, 2011
Table 34: Celgene Corporation – Oncology Pipeline, 2011
Table 35: Celgene Corporation – SCLC Pipeline
Table 36: Cephalon Inc. – Oncology Pipeline, 2011
Table 37: Cephalon Inc. – SCLC Pipeline
Table 38: SCLC Therapeutics, Global, Deals, 2011

1.2 List of Figures
Figure 1: SCLC – Tumor Formation in Lungs
Figure 2: SCLC Treatment Algorithm by Stage
Figure 3: SCLC Disease Progression
Figure 4: SCLC Anatomic Stage Classification
Figure 5: SCLC Treatment Options by Stage
Figure 6: SCLC Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 7: SCLC Therapeutics, Market Share ($m), 2010
Figure 8: SCLC Therapeutics Market, Global, Forecast ($m), 2010–2018
Figure 9: SCLC Therapeutics, Market Share ($m), 2018
Figure 10: SCLC Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 11: SCLC Therapeutics Market, The US, Forecast ($m), 2010–2018
Figure 12: SCLC Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 13: SCLC Therapeutics Market, The UK, Forecast ($m), 2010–2018
Figure 14: SCLC Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 15: SCLC Therapeutics Market, France, Forecast ($m), 2010–2018
Figure 16: SCLC Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 17: SCLC Therapeutics Market, Germany, Forecast ($m), 2010–2018
Figure 18: SCLC Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 19: SCLC Therapeutics Market, Italy, Forecast ($m), 2010–2018
Figure 20: SCLC Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 21: SCLC Therapeutics Market, Spain, Forecast ($m), 2010–2018
Figure 22: SCLC Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 23: SCLC Therapeutics Market, Japan, Forecast ($m), 2010–2018
Figure 24: SCLC Therapeutics, Key Events Impacting Future Market
Figure 25: Opportunity and Unmet Need in the First-line Treatment of SCLC Therapeutics Market, 2011
Figure 26: Opportunity and Unmet Need in the Relapsed/Refractory Treatment of SCLC Therapeutics Market, 2011
Figure 27: SCLC Therapeutics Market – Strategic Competitor Assessment, First-Line Treatment, 2011
Figure 28: SCLC Therapeutics Market – Strategic Competitor Assessment, Treatment of Relapse/ Refractory, 2011
Figure 29: SCLC Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 30: SCLC Market – Clinical Pipeline by Mechanism of Action, 2011
Figure 31: Technology Trends Analytical Framework of The SCLC Pipeline, 2011
Figure 32: SCLC Therapeutics –Technology Trends Analytical Framework of the SCLC Pipeline – Description, 2011
Figure 33: SCLC Therapeutics – Clinical Trials by Country, 2011
Figure 34: SCLC Therapeutics – Clinical Trials by Phase, 2011
Figure 35: SCLC Therapeutics – Clinical Trials by Status, 2011
Figure 36: SCLC Therapeutics – Clinical Trials by Overall Sponsors, 2011
Figure 37: SCLC Therapeutics – Clinical trials by Prominent Sponsors, 2011
Figure 38: Top Companies Participating in SCLC Therapeutics Clinical Trials, 2011
Figure 39: SCLC Therapeutics, Strategic Assessment, 2011
Figure 40: SCLC Therapeutics Market – Clinical Pipeline by Company, 2011
Figure 41: Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global SCLC therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SCLC therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The SCLC Therapeutics Market is Forecast to Show Steady Growth until 2018

GlobalData’s analysis estimated the Small Cell Lung Cancer (SCLC) therapeutics market to be worth $277.8m in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.4% for the next eight years to reach $362.3m by 2018. The growth during 2005-2010 is primarily attributed to the launch of an oral form of Hycamtin (topotecan). The steady growth rate during the forecast period is attributed to the expected launch of Amrubicin (SM-5887) in the US and Europe for the treatment of relapse/refractory SCLC patients, and a weak late stage pipeline with no molecules to treat newly diagnosed patients.

SCLC Therapeutics Market, Global, Revenue and Forecast ($m), 2005-2018

Sources: Govindan R et al, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database, J Clin Oncol. 2006 Oct 1; 24(28):4539-44; Sawabata N et al, A Japanese lung cancer registry study at 2002, Nihon Kokyuki Gakkai Zasshi. 2010 Apr; 48(4):333-44; Janssen-Heijnen ML et al, The changing epidemiology of lung cancer in Europe, Lung Cancer. 2003 Sep;41(3):245-58; GLOBOCAN 2008; National Cancer Institute (NCI); Annals of Oncology; Oxford Journal; Cancer Facts and Figures; SEER Stat Fact Sheets, Myeloma; I Tumori In Italia – Rapporto Airtum 2010, 2010, 34(5-6), supplement 2, 132-133; DKG krebsgesellschaft; Dominique Maraninchi et al, “La situation du cancer en France en 2009”; GlobalData; GlobalData Epidemiology-based Market Forecasting Model; Primary Research Interviews; KOL Interviews.

Celgene Corporation
Cephalon Inc.

Customers who bought this item also bought

• RNA Interference (RNAi) - Global Strategic Business Report
• Global Migraine Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
• Intranasal Drug Delivery - Global Business Strategic Report
• Global Schizophrenia Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
• Regenerative Medicine - Global Strategic Business Report
• CNS Therapeutics - Global Strategic Business Report
• Herpes Simplex Virus Treatment - Global Strategic Business Report
• Pediatric Drugs and Vaccines - Global Business Strategic Report
• Global Biopharmaceutical Market Report & Forecast (2012-2017)
• Ion Channel Modulators - Global Strategic Business Report